|
Age, years*
|
67 (24–88)
|
|
Male sex, n (%)
|
66 (72.5)
|
|
APACHE II*
|
11 (2–28)
|
|
Co-morbidities, n (%):
|
|
Malignancy
|
14 (15.4)
|
|
Cardiovascular
|
26 (28.6)
|
|
Pulmonary
|
33 (36.3)
|
|
Diabetes Mellitus
|
21 (23.1)
|
|
Urogenitala
|
14 (15.4)
|
|
Hepatic
|
8 (8.8)
|
|
Haematologicalb
|
12 (13.2)
|
|
Neurologicalc
|
18 (19.2)
|
|
Charlson score*
|
4 (0–10)
|
|
McCabe score**
|
1.48 ± 0.64
|
|
Patients with CKD1 at baseline
|
19 (20.9)
|
|
Type of infection, n (%):
|
|
Pneumonia
|
24 (24.6)
|
|
Urinary tract infection
|
22 (24.2)
|
|
Skin and soft tissue infection
|
11 (12.1)
|
|
Organ space surgical site infection
|
10 (11)
|
|
Bacteremia
|
6 (6.6)
|
|
Other
|
18 (19.8)
|
|
Hospital-acquired infection, n (%)
|
86 (94.5)
|
|
Department of hospitalization:
|
|
Medical
|
44 (48.2)
|
|
Surgical
|
32 (35.2)
|
|
ICU2
|
15 (16.2)
|
|
Admission diagnosis category:
|
|
Infection
|
26 (28.6)
|
|
Other-medical
|
35 (38.5)
|
|
Other-surgical
|
30 (33)
|
|
CMS3 daily dose (millions of IU4)**
|
5.45 ± 2.21
|
|
CMS3 total dose (millions of IU4)**
|
108.36 ± 96.41
|
|
CMS3 duration of treatment, days**
|
20.18 ± 16.01
|
|
Inhaled CMS3, n (%)
|
14 (15.4)
|
|
Combined antimicrobial therapy, n (%)
|
46 (50.5)
|
|
Css
5 (mg/L)**
|
1.67 ± 1.42
|
|
Css
5 > 1.28 (mg/L), n (%)
|
46 (50.5)
|
|
Css
5/MIC6**
|
3.43 ± 2.91
|
|
AKI7 prior to CMS3 treatment, n (%)
|
12 (13.2)
|
|
Patients with AKI at day 7, n (%)
|
|
R (Risk)
|
19 (20.9)
|
|
I (Injury)
|
9 (9.9)
|
|
F (Failure)
|
2 (2.2)
|
|
Patients with AKI7 at the EOT8, n (%)
|
|
R (Risk)
|
12 (13.2)
|
|
I (Injury)
|
27 (27.7)
|
|
F (Failure)
|
10 (11)
|
|
Clinical response, n (%)
|
72 (79.1)
|
|
30-Day all-cause mortality, n (%)
|
28 (30)
|
|
Hospital length-of-stay (days)*
|
67 ± 53.97
|
